Evidence map›Paper›PMID 38434525›Full record

ArticleHemaSphere2024

Immunodeficient NBSGW mouse strain allows chemotherapy modeling in AML patient-derived xenografts.

Vilma Dembitz, Jozef Durko, Joana Campos, Sophie C James, Hannah Lawson, Kamil R Kranc, Paolo Gallipoli

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in HemaSphere, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Vilma DembitzCentre for Haemato-Oncology, Barts Cancer Institute Queen Mary University of London London UK.ORCID 0000-0002-9463-253X
Jozef DurkoCentre for Haemato-Oncology, Barts Cancer Institute Queen Mary University of London London UK.
Joana CamposCentre for Haemato-Oncology, Barts Cancer Institute Queen Mary University of London London UK.
Sophie C JamesCentre for Haemato-Oncology, Barts Cancer Institute Queen Mary University of London London UK.
Hannah LawsonCentre for Haemato-Oncology, Barts Cancer Institute Queen Mary University of London London UK.
Kamil R KrancCentre for Haemato-Oncology, Barts Cancer Institute Queen Mary University of London London UK.
Paolo GallipoliCentre for Haemato-Oncology, Barts Cancer Institute Queen Mary University of London London UK.ORCID 0000-0001-7254-2253
Queen Mary University of London · GBInstitute of Cancer Research · GB

Funding

Cancer Research UK 26787Cancer Research UK 27964Medical Research Council MR/P010008/1Medical Research Council MR/P010008/2
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID38434525
PMCPMC10878184
OpenAlexW4391283896

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.